Previous Article | Next Article ![]()
Journal of Bacteriology, April 2001, p. 2241-2248, Vol. 183, No. 7
Division of Infectious Diseases, University
of Illinois at Chicago College of Medicine, Chicago, Illinois
60612,1 and Department of Biochemistry,
The Medical College of Wisconsin, Milwaukee, Wisconsin
532262
Received 30 October 2000/Accepted 11 January 2001
Elongation factor 3 (EF3) is considered a promising drug target for
the control of fungal diseases because of its requirement for protein
synthesis and survival of fungi and a lack of EF3 in the mammalian
host. However, EF3 has been characterized only in ascomycete yeast. In
order to understand the role of EF3 in a basidiomycete yeast, we cloned
the gene encoding EF3 from Cryptococcus neoformans
(CnEF3), an important fungal pathogen in immunocompromised patients, including those infected with human immunodeficiency virus.
CnEF3 was found to encode a 1,055-amino-acid protein and has 44% identity with EF3 from Saccharomyces cerevisiae
(YEF3). Expressed CnEF3 exhibited ATPase activity that was
only modestly stimulated by ribosomes from S. cerevisiae.
In contrast, CnEF3 showed tight binding to cryptococcal ribosomes, as
shown by an inability to be removed under conditions which successfully
remove Saccharomyces EF3 from ribosomes (0.5 M KCl or 2 M
LiCl). CnEF3 also poorly complemented a YEF3
defect in a diploid null mutant and two temperature-sensitive mutants
which have been shown previously to be complemented well by
EF3 from other ascomycetes, such as Candida
albicans. These data clearly identify the presence of a
functioning EF3 in the basidiomycete yeast C. neoformans, which demonstrates an evolutionary divergence from
EF3 of ascomycete yeast.
Cryptococcus neoformans
is an important fungal pathogen which causes a lethal
meningoencephalitis in a significant number of persons with AIDS and
afflicts an increasing number of immunocompromised patients on
steroids, chemotherapy, or posttransplant immunosuppressives (18). Therapy of cryptococcosis is limited by toxicity of
such agents as amphotericin B (1); newer agents such as
the azole inhibitors are less toxic, but increasing reports of
resistance may limit their eventual usefulness (3, 15,
17). Echinocandins and pneumocandins are important new
antifungal agents which are inhibitors of 1,3- Elongation factor 3 (EF3) has been shown to be a required translation
cofactor in the ascomycete Saccharomyces cerevisiae (7). The factor is also present in a variety of pathogenic ascomycete fungi, including Candida albicans
(8) and the pathogen Pneumocystis carinii
(34), which has been shown to be closely related to
ascomycete yeasts based on analysis of its rRNA gene as well as genes
encoding dihydrofolate reductase, thymidylate synthetase, While studies in model yeasts such as the ascomycete
Saccharomyces may yield important information about
essential biological systems, recent advances in the molecular biology
of C. neoformans allow the study of drug targets such as EF3
in the pathogen itself, allowing direct application of findings to the
rational design of antifungal agents. The present study seeks to
identify and characterize EF3 from C. neoformans in order to
extend the role for this factor to basidiomycete fungi. This will allow
further study of its properties in protein translation and may enable the design of antifungal compounds directed against recombinant cryptococcal EF3.
Strains.
C. neoformans ATCC 34873 was a generous
gift of K. J. Kwon-Chung. S. cerevisiae strain BJ3505/G
was from Eastman Kodak (New Haven, Conn.). Escherichia coli
SURE (Stratagene, La Jolla, Calif.) was the host strain used for
screening the cDNA library after mass excision of the Uni-Zap cDNA
library. E. coli XL1-Blue (Stratagene) was the recipient
strain of the Bluescript phagemid following in vivo excision for the
Uni-Zap XR vector (Stratagene)-containing cDNA clones. E. coli DH10B (Life Technologies, Bethesda, Md.) was the host strain
for recovery of ligated plasmids.
Enzyme assay.
The pyruvate kinase/lactate
dehydrogenase-coupled ADP assay for EF3 ATPase activity was performed
according to the method of Sarthy et al.(25).
Activity was expressed in nanomoles of ADP produced per minute at
30°C.
Nested PCR amplification and screening a cryptococcal cDNA
library.
A stationary-phase cryptococcal cDNA library in Uni-Zap
described previously (32) was mass excised and inserted
into E. coli SURE according to the manufacturer's
directions (Stratagene). Library plasmid was prepared from cells
(Qiagen, Valencia, Calif.) and subjected to endonuclease digestion with
NotI. Linearized library plasmids were used as the template
(50 ng) and subjected to 25 cycles of amplification by PCR using
Taq polymerase (Life Technologies, Bethesda, Md.), an
annealing temperature of 40°C, and degenerate primers constructed
from amino acid sequence contained in two of the ATP-binding regions of
S. cerevisiae EF3 (20) (primer 1360S,
CCNAAYGGNTGYGGNAAA, and primer 2760A,
RTARTTNGTNGGYTCRTC). Products of 1,200 to 1,800 bp were gel
purified and subjected to a second round of 25 cycles of PCR
amplification using an annealing temperature of 48°C and internal
degenerate primers from S. cerevisiae EF3 (primer 1690S,
GAYCCNACNAAYCAT, and primer 2100A, YTTNCCNGCNCCRTTNGG). A 420-bp single band was gel purified, labeled with
[ Northern and Southern blot analysis of CnEF3.
Cryptococcal cells were grown to mid-log phase
(A600 < 1.0), and total RNA was obtained
as described (32). DNA was obtained from cryptococcal
cells as described (30). Northern blots were performed by
standard methods (23) using CnEF3 from plasmid p5a.
Construction of expression plasmid pmyep.NS-CnEF3.
A
double-stranded oligonucleotide (sense,
TCGACCACCACCACCACCACCACTAGGCTAGC; antisense,
TAGCCTAGTGGTGGTGGTGGTGGTGG) was inserted into S. cerevisiae expression plasmid YEpFLAG-1 (IBI/Kodak, Rochester, N.Y.) between restriction sites ApaI and SacII to
produce the plasmid pmyep (pmyep was kindly obtained from K. Williamson). The Flag affinity tag and hydrophobic leader sequence were
removed from pmyep by divergent PCR using primers YEP-1496S
(GCCGCCGAATTCCTCGAGCCCGGG) and YEP-1217A
(GCCGCCGAATTCTGAAGGAAATCTCATCGC) to create plasmid myep.NS.
Plasmid myep.NS was selected for its correct size, ability to transform
S. cerevisiae strain BJ3505/G by a polyethylene
glycol-lithium acetate (PEG-LiAc) protocol (Stratagene), and the
presence of an a EcoRI site. The CnEF3 open
reading frame (ORF) was PCR amplified using Pfu polymerase
(Stratagene, La Jolla, Calif.) using primers CnEF-5Ba
(GCCGCCGGATCCCTCCTGCTGCTACCGCTGCTG) and CnEF3Apa1
(GCCGCCGGGCCCAAGCTCTTCATCACTGAAGAC). The amplified product
was restriction endonuclease digested with BamHI and
ApaI and inserted into the respective sites of myep.NS to
produce plasmid myns.CnEF3.1. Use of the multiple cloning site of
myep.NS resulted in a 43-nucleotide addition to the 5' region of the
CnEF3 ORF, resulting in a putative polypeptide having 14 additional amino acids at the N terminus with the sequence
MRFPSEFREIYRWIP. Integrity of sequence was verified by
automated sequencing of the CnEF3 ORF (CRC-DNA Sequencing Facility).
Expression and purification of recombinant CnEF3.
S.
cerevisiae strain BJ 3505/G was transformed with myns.CnEF3.1 by
means of a PEG-LiAc protocol (Stratagene). Transformants containing the
myns.CnEF3.1 plasmid were selected by Southern blot and for ability to
overexpress a 116-kDa protein band on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (approximately
20-fold that of untransformed BJ3505/G). To induce recombinant protein,
a selected transformant was grown in yeast expression medium (3%
glycerol, 1% glucose, 20 mM CaCl2, 1% yeast extract, 8%
peptone) according to the manufacturer's instructions (Invitrogen).
Cells were isolated by centrifugation and subjected to glass bead (0.45 µm) breakage in a Braun homogenizer (Germany) for 1.5 min at 4°C in
buffer A containing 10 mM Tris-HCl(pH 7.5), 10 mM MgSO4,
0.2 mM EDTA, and 10% glycerol. Cell debris was removed by
centrifugation, and the supernatant was adsorbed on a 20-ml column of
carboxymethyl (CM)-Sepharose equilibrated in buffer A, washed, and
eluted with buffer A containing 100 mM KCl. Fractions were assayed by
SDS-PAGE, and fractions containing the predominant 116-kDa band were
pooled, dialyzed in buffer B (20 mM Tris-HCl pH[7.0], 50 mM KCl, 10 mM magnesium acetate, 0.2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 1 mM dithiothreitol [DTT], 10% [vol/vol] PMSF, glycerol)
and adsorbed on a 1-ml ATP-agarose column (Sigma) equilibrated in
buffer C, and then washed and eluted with buffer C containing 2 mM ATP.
Fractions were again assayed on SDS-PAGE, and suitable fractions were
pooled, tested for ATPase activity, and subjected to N-terminal sequencing.
Cryptococcal ribosome isolation.
The method used was based
on that by Otaka and Kobata (16). Briefly, cryptococcal
cells were grown in 2 liters of YPD (2% glucose, 1% yeast extract,
2% Bactopeptone) to an A600 of 0.8, followed by
homogenization in a Braun homogenizer using 0.46-µm glass beads for 2 min at 4°C. Two milliliters of cold buffer A (50 mM Tris-HCl [pH
7.0], 50 mM NH4Cl, 10 mM magnesium acetate, 5 mM DTT, 0.1 M EDTA, 0.2 mM PMSF, 10% glycerol) was added, and the mixture was
centrifuged at 5,000 × g for 10 min. The supernatant was clarified by centrifuging twice at 35,000 × g for
15 min, and the supernatant was then centrifuged for 3 h at 4°C
at 150,000 × g. The pellet from the 150,000 × g centrifugation was resuspended in buffer B (buffer A plus 0.5 M KCl) and centrifuged at 10,000 × g for 10 min to
remove aggregates, and the supernatant was overlaid on a cushion of
buffer C (buffer B plus 25% glycerol) and centrifuged at
150,000 × g at 4°C for 3 h, and the pellet was
recovered. These two sets of low-speed and high-speed centrifugations
were repeated once again in the same way, and the pellet was
resuspended in buffer A containing 25% glycerol. Cryptococcal
ribosomes were also prepared in the presence of buffers excluding 0.5 M
KCl. Cryptococcal ribosomes were assayed by ultracentrifugation using a
5 to 30% sucrose gradient (110,000 × g for 10 h)
and showed a protein profile similar to that of S. cerevisiae ribosomes prepared as described (16).
Antibody production to recombinant CnEF3.
Purified
recombinant cryptococcal EF3 was subjected to SDS-PAGE, and the 116-kDa
band was excised, homogenized in the presence of Freund's adjuvant,
and administered to 6-week-old CAF1/J mice (20 µg of protein/mouse)
by intraperitoneal injection on days 0, 21, 49 and 74. Serum was
obtained from the mice prior to the first injection and 1 week after
the fourth injection. Western blots and dot blots were performed using
the indicated amount of protein and primary antibody and a 1:1,000
dilution of horseradish peroxidase (HRP)-labeled anti-mouse
immunoglobulin (Ig) antibody (Accurate Antibodies, Westbury, N.Y.).
ELISA.
For the enzyme-linked immunosorbant assay (ELISA),
96-well plates were incubated with antigen (10 mg/mlµ) overnight at
4°C, washed three times with phosphate-buffered saline (PBS), and
blocked with 5% milk for 1 h. The serum was then diluted as
indicated with PBS and added to the wells. Following an overnight
incubation at 4°C, the wells were washed PBS, and then alkaline
phosphatase-labeled goat anti-mouse Ig antibody (1:2,000 dilution) was
added. After incubation at room temperature for 1 h, the wells
were washed with PBS, 3 mM p-nitrophenyl phosphate in 0.05 M
NaCO3-0.05 mM MgCl2 was added, and the optical
density of 405 nm of the wells was read on a microtiter plate reader
(Titertek, Huntsville, Ala.).
Construction of complementation plasmid Y24EF-CnEF3 7.
Divergent PCR in the direction away from the plasmid insert was used to
remove the S. cerevisiae EF3 ORF and insert a
NotI site into plasmid YEpEF3 using primers YE24-EF5
(GCCGCCGCGGCCGCATCTTTTAATGTTATCGATGGATT) and YE24-EF3
(GCCGCCGCGGCCGCATCACTGCTTTCACAGTTTTCTT). The modified YepEF3 plasmid retained sufficient 5' untranslated region and 3'
termination sequence necessary for complementation and expression in
S. cerevisiae (24). Plasmid YEpEF3 Nucleotide sequence accession number.
The nucleotide
sequence data reported in this paper have been submitted to GenBank and
assigned accession number AF316889.
Isolation and sequence of C. neoformans EF3 gene.
Initial unsuccessful cloning attempts using full-length S. cerevisiae EF3 cDNA clones suggested poor conservation of
nucleotide sequence of this factor between ascomycetes and
basidiomycetes. Thus, a nested PCR approach was used to produce a
suitable probe for cloning using fully degenerate oligonucleotide
primers derived from conserved S. cerevisiae sequence within
the ATP-binding cassettes and use of a cryptococcal cDNA template from
a mass-excised stationary-phase library of C. neoformans to
avoid untranscribed sequences. This approach yielded a single 420-bp
amplified fragment of the expected size (Fig.
1A), which was then radiolabeled and used
to screen a C. neoformans cDNA library (a gift from J. Edman). Two cDNA clones of appropriate size were obtained; p5a was
selected, and both strands were sequenced. Southern blots of
cryptococcal DNA showed the presence of a single-copy gene (Fig. 1B)
using restriction enzymes predicted to cut outside the CnEF3
ORF according to sequence generated from clone p5a. Northern blot
analysis of CnEF3 showed the presence of a 3.1-kb transcript
which was present in cells obtained in log-phase growth (Fig. 1C).
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.7.2241-2248.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Evolutionary Divergence of an Elongation Factor 3 from Cryptococcus neoformans
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-glucan
synthetases and show excellent activity against
ascomycete pathogens such as Candida albicans
and Aspergillus fumigatus, but alterations in this enzyme
from basidiomycetes make this important class of agents ineffective
against C. neoformans (27). The latter example
shows the potential gap in antifungal coverage which may occur when
inhibitors are chosen without consideration of possible evolutionary
differences in drug targets within various fungal pathogens.
-tubulin,
and ATP (for a review, see reference 31). While an
anti-EF3 antibody has been shown to react with basidiomycete yeasts
(4), EF3 has not been characterized from this class of
fungi. When present, EF3 is a required translational cofactor essential
for growth of the organism. EF3 is believed to modulate the inverse
relationship between protein translation rate and amino acid fidelity
by altering the binding affinities of the ternary complex to the
ribosomal A site and that of the deacylated tRNA to the E site
(29). It is unique among the translational factors in that
it is not present or required in mammalian translational systems
(4). This makes EF3 a putative drug target for a wide variety of fungal pathogens while offering the possibility of a
favorable side effect profile in the mammalian host. Many valuable antibacterial agents such as the macrolides and aminoglycosides are
inhibitors of the prokaryotic translational apparatus. These antibiotics have had a profound and long-lasting impact on the outcome
of bacterial infections and show the extensive precedent for the role
of translational inhibitors in the chemotherapy of infectious agents.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-32P]ATP, and used to screen the cryptococcal
stationary-phase cDNA library by standard techniques (23).
Clone p5a was selected based on the size of its insert and its ability
to bind the PCR probe described above, and both strands were sequenced
by automated methods (CRC-DNA Sequencing Facility, University of Chicago).
-4 was
selected for its correct size, ability to transform S. cerevisiae strain BJ3505/G by a PEG-LiAc protocol (Stratagene),
and presence of a NotI site. The CnEF3 ORF was
PCR amplified in from NotI endonuclease-treated p5a using
Pfu polymerase (Stratagene) and primers Crypto 5 (GCCGCCGCGGCCGCCTGCTACCGCTGCTGCCTC) and Crypto 3 (GCCGCCGCGGCCGCTTAAAGCTCTTCATCACTGAAGA). The amplified fragment was ligated to NotI digested plasmid YEpEF3
-4.
Insertion of the NotI site resulted in a nine-nucleotide
substitution after the ATG codon of the ORF which would be expected to
lead to a two-amino-acid alteration of the CnEF3 ORF at the
N terminus, resulting in an expected N-terminal sequence of MRPPATA in
the recombinant protein. Suitable clones were screened for the presence of a suitably sized insert in the correct orientation by means of PCR
using appropriate primers. Clone Y24EF-CnEF3#7 was further characterized by automated sequencing (CRC-DNA Sequencing Facility) to
establish fidelity of sequence.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (40K):
[in a new window]
FIG. 1.
Cloning and characterization of cryptococcal EF3. (A)
Lane 1, 100-bp ladder; lane 2, PCR-amplified product from cryptococcal
cDNA library. (B): Southern blot of CnEF3. Digestions: lane
1, SpeI and BamHI; lane 2, SpeI and
ApaI; lane 3, SpeI and XbaI; lane 4, SpeI alone. (C) Northern blot of CnEF3. (D)
SDS-PAGE of 1 µg of recombinant cryptococcal EF3. (E) Western blot of
whole-cell extract of C. neoformans (lane 1) and 1 µg of
purified recombinant CnEF3 (lane 2).
Analysis of CnEF3 suggests evolutionary sequence
divergence from other fungi.
Clone p5a was found to contain a
3,447 bp insert containing a 3,165-bp. ORF which encoded a putative
1,055 amino acid polypeptide having a calculated molecular mass of
116.4 kDa (Fig. 2).
Amino acid sequence was used to query
the nonredundant combined nucleotide databases of GenBank, EMBL, DDBI,
and PDB using MacVector software and the Blast search engine
(1). Comparison of amino acid sequence showed significant
amino acid homology to EF3 of S. cerevisiae, especially
within the two ATP-binding "cassettes" (motifs A and B). Overall
conservation of amino acid sequence between C. neoformans and S. cerevisiae (44% identity) is lower than that
reported between S. cerevisiae and Candida (78%
identity) (8) and between S. cerevisiae and
Pneumocystis (57% identity) (34). In addition, there is no serine at position 277, a proposed phosphorylation site for
EF3 in S. cerevisiae (20). However, there were
three putative phosphorylation sites that were conserved between
ascomycetes and C. neoformans, T244,
T680, and T772. There were also observed regions of homology between ribosome-binding sites within the N
terminus and C terminus of the CnEF3 protein.
|
Production and analysis of recombinant cryptococcal EF3.
To assess the ability of cryptococcal EF3 to function with
S. cerevisiae ribosomes, recombinant CnEF3 was
heterologously expressed in S. cerevisiae using a new
expression plasmid, pmyep.NS, designed for intracellular
expression of proteins using the ADH2-promoter. Plasmid
pmyep was constructed from the yeast expression plasmid FLAG1 by
addition of a terminal histidine affinity tag, divergent PCR was used
to remove the pro-
-leader sequence, and Flag affinity sequence was
used to construct plasmid pmyep.NS. The CnEF3 ORF was
inserted into pmyep.NS and used to transform S. cerevisiae. Transformed yeast cells expressed 20-fold-higher levels of CnEF3 over
background YEF3. Recombinant CnEF3 was successfully purified from
native YEF3 because CnEF3 did not bind to negatively charged affinity
matrices and showed only minimal binding to positively charged matrices
such as DEAE-Sepharose (eluted with 0.1 M KCl) in contrast to YEF3,
which binds more strongly to both (25). As shown in Fig.
1D, recombinant cryptococcal EF3 purified as a 116 kDa protein,
consistent with its predicted size based on cDNA sequence. Western blot
analysis of cryptococcal cell extract using antibody prepared from
recombinant CnEF3 showed a single band at 116 kDa (Fig. 1E) which
showed no reactivity against Saccharomyces cell extracts,
ribosomes, or EF3 (data not shown). N-terminal sequencing of the
purified factor showed exclusively the expected CnEF3 fusion protein
sequence MRFPS. Steady-state kinetics of ATP hydrolysis by CnEF3 using
heterologous S. cerevisiae ribosomes showed a
ribosome-dependent alteration in Km (709 µM
with versus 318 µM without ribosome), whereas there was no
significant ribosome-dependent alteration in
Vmax (11 versus 13 nM/min). This is in contrast to previous work showing a 100-fold increase in
Vmax of the S. cerevisiae factor with
the same species ribosomes (9). The stimulation in
Km observed in the present case was also not as marked as that reported previously for Saccharomyces EF3 and
may be due to a suboptimal interaction between CnEF3 and ribosomes from
S. cerevisiae. It is possible that the suboptimal
interaction between recombinant CnEF3 and ribosomes could have been due
to the additional 14 amino acids at the N terminus of the expressed protein construct, although a lack of significant homology between the
elongation factors within the first 100 amino acids makes this less
likely to be a region of critical importance. Stimulation of CnEF3 by
cryptococcal ribosomes could not be assessed because of an inability to
remove ATPase activity from cryptococcal ribosomes, as described in the
next section. Western blot of whole cryptococcal extract using an
anti-CnEF3 antibody showed a single 116-kDa band, consistent with the
size of the recombinant protein and the expected size based on the cDNA
sequence (Fig. 1E). Anti-CnEF3 antibody did not cross-react with either
cell wall extract or ribosomes from S. cerevisiae (data not shown).
Analysis of CnEF3 binding to cryptococcal ribosomes.
Typically, extraction with 0.5 M KCl removes essentially all
ATPase activity from S. cerevisiae ribosomes and
allows the ready separation of elongation factors from ribosomal
proteins in S. cerevisiae systems. In contrast, we found
that extraction of C. neoformans ribosomes yielded a
preparation with a large amount of residual ATPase activity which
prevented assay of ribosome-dependent ATPase activity of the
cryptococcal EF3. For example, ribosomes prepared in the absence of 0.5 M KCl exhibited ATPase activity of 78 nmol min
1
A260-rib
1 which, after washing
three times with 0.5 M KCl, continued to show an ATPase
activity of 200 nmol min
1
A260-rib
1. (An increase in ATPase activity
with washing may have been due to the removal of ATPase inhibitors.)
Since one source of ATPase activity could be cryptococcal EF3, we
investigated the binding properties of the cryptococcal factor for its
homologous ribosome. Dot-blot analysis of nitrocellulose-absorbed
cryptococcal ribosome preparations showed that extraction of ribosomes
with 0.5 M KCl, 1 M LiCl, or 2 M LiCl did not remove significant
amounts of immunoreactive EF3 from the ribosome preparation (Fig.
3A). Western blot of 0.5 M KCl-washed
ribosomes using anti-CnEF3 antibody showed an immunoreactive band at
116 kDa, consistent with the presence of CnEF3 (data not shown). These
conditions have been shown previously to remove S. cerevisiae but not mammalian ATPase activity from ribosomes (13).
|
Complementation between YEF3 of S. cerevisiae and CnEF3 of C. neoformans.
Diploid strain KC44 of S. cerevisiae,
bearing one wild-type and one disrupted YEF3 gene
(MATa/ MAT
yef3::LEU2/leu2-3,112/leu2-3,112 lys2/+
met2-1/+trp1-7/+ura3-52/ura3-52)
(24) was transformed with plasmid-borne CnEF3
driven by the YEF3 promoter in a 2µm, Y24 vector
(y24-CnEF3.7). The diploid yeasts were sporulated and dissected by
standard protocols (26). The viable spores showed a
segregation pattern of 2:2, 3:1, and 4:0. In all dissected spores, two
of the spores grew equally to the wild-type strain, while the rest grew
at a much slower rate (data not shown). Complementation of two strains
of haploid S. cerevisiae bearing a temperature-sensitive mutation in the YEF3 gene (strains ts22 and ts27) revealed
the appearance of significantly slower-growing colonies at the
nonpermissive temperature of 34°C. Similar complementation with
wild-type YEF3 genes from S. cerevisiae and
C. albicans gave normal-sized colonies, as reported
previously (6, 8). From these results, we conclude that
CnEF3 complements the function of YEF3 poorly,
although it does show that CnEF3 has functional capability.
To verify that the cryptococcal factor was expressed from y24-CnEF3.7
under the YEF3 promoter, CnEF3 protein was purified from
ts22 complemented with y24-CnEF3.7 using the purification procedure
which resolves CnEF3 from YEF3 (see Materials and Methods). The protein
was readily expressed at the permissive temperature as a protein having
the predicted 116-kDa size on SDS-PAGE, intact ATPase activity
(Vmax = 90 mol/min/mg), and the expected
unique N-terminal sequence of the cryptococcal fusion protein from
Y24EF-CnEF3#7, MRPPA. It is possible that poor complementation was due
to the two-amino-acid substitution in the N terminus of the
cryptococcal fusion protein, although this is unlikely, as very little
homology exists between the cryptococcal factor and the
Saccharomyces factor in the first 100 amino acids of the N terminus.
| |
DISCUSSION |
|---|
|
|
|---|
While EF1 and EF2 are required for efficient protein translation for all eukaryotic organisms, EF3 is unique in its identification and requirement only within the kingdom Fungi. Since inhibition of protein synthesis by targeting EF3 might represent an effective drug strategy for the control of fungal diseases, identification and characterization of this factor among diverse fungi of medical importance are essential to allow design of pharmacological inhibitors having the broadest application. Thus far, EF3 has only been cloned and characterized from yeasts of the order Ascomycota as well as the fungus-like organism Pneumocystis carinii (6). Basidiomycete yeasts are distinct from ascomycete yeasts in both morphology (2) and 18S ribosomal DNA sequence criteria (21). Of the more than 20,000 species described (11), C. neoformans represents the most important human pathogen within this phylum. Various properties of this fungus, such as less efficient homologous recombination, complex transcriptional processes, and a promiscuous telomerase (2), suggest that essential cellular machinery may be distinct from that in the more highly studied ascomycetes such as S. cerevisiae and Neurospora crassa.
In order to compare the functional properties of EF3 among fungi, we undertook the characterization of EF3 from the basidiomycete C. neoformans. Consistent with its more distant relationship to the ascomycetes, CnEF3 showed less homology to EF3 from S. cerevisiae (46% identity) than to EF3 from ascomycetes such as C. albicans (78% identity to S. cerevisiae) and the ascomycete-like organism P. carinii (57% identity to S. cerevisiae) (5). An EF3-like gene cloned from the Chlorella virus shows a similar low identity (36%), but the functional significance of this latter gene has not been established (33). In contrast, the homology of EF1 between the two classes is much higher (84.7% identity) (28) and suggests a greater evolutionary drift of the third translational cofactor within phyla of Fungi. Low identity between CnEF3 and ascomycete fungi may also help in determining the functional significance of amino acids within the protein. For example, lack of a conserved serine at position 277, corresponding to a proposed phosphorylation site in YEF3 (19), makes this amino acid unlikely to have a role in regulation by phosphorylation in C. neoformans. In contrast, important ATP-binding regions A and B that form the ATP-binding cassette are conserved in CnEF3, consistent with their role in ATP hydrolysis and protein translation in Saccharomyces (4).
Ribosome binding is believed to be an important function of EF3 and to be essential for the factor's translation-modulating effects (29). Analysis of peptide regions of EF3 believed to be involved in ribosome binding may shed light on possible structural differences in EF3-ribosome binding interactions between ascomycetes and basidiomycetes. Previous studies have shown that an acidic N-terminal region of S. cerevisiae (amino acids 98 to 388) (10) and a basic C-terminal region (775 to 1044) (12) of EF3 are both involved in ribosome binding. Comparison of the amino acid sequence of the homologous regions of CnEF3 (N-terminal residues 108 to 404 and C-terminal residues 796 to 1055) show that the cryptococcal N-terminal region is less acidic (12 versus 17 D and 16 versus 23 E) with a calculated pI of the cyptococal fragment of 8.98 versus 4.85 for the S. cerevisiae fragment. In addition, the cyptococal C-terminal fragment is much less basic (26 versus 31 K), yielding a calculated pI of 6.73, versus 8.82 for the S. cerevisiae fragment. Indeed, differences in surface charge of the cryptococcal factor were also suggested by its lack of binding to CM-cellulose and its relatively poor binding to DEAE-cellulose, in contrast to the stronger binding of the S. cerevisiae factor to both matrices. Such differences in amino acid sequence and CnEF3 binding characteristics suggest an evolutionary drift in the nature of CnEF3-ribosome binding from that of ascomycetes.
Recombinant CnEF3 showed significant ATPase activity, as has been shown for YEF3 (4). Since ribosome-dependent ATPase activity is a key characteristic of EF3, the ability of S. cerevisiae ribosomes to stimulate CnEF3 ATPase activity was assessed. While previous reports have shown a 50- to 100-fold increase in Vmax of YEF3 ATPase activity in the presence of homologous ribosomes, we found no significant increase in ATPase Vmax of the cryptococcal EF3 in the presence of S. cerevisiae ribosomes and only a small decrease in Km. This suggests that evolutionary divergence from ascomycetes exhibited by the CnEF3 sequence results in alterations in properties leading to poor EF3-S. cerevisiae ribosome interactions.
In order to study the nature of the interaction of CnEF3 with cryptococcal ribosomes, attempts were made to remove CnEF3 from a ribosome preparation with 0.5 M KCl, which typically removes all S. cerevisiae elongation factors. Even after extraction with potassium (0.5 M) or lithium (2 M) salts, significant ribosome-ATPase activity remained, preventing the measurement of CnEF3-cryptococcal ribosome-dependent ATPase activity. Both dot-blot and sucrose sedimentation experiments showed that CnEF3 exhibited an unusually strong binding to ribosomes, which may account for at least part of the observed residual ATPase activity of salt-extracted cryptococcal ribosomes. It is interesting that in higher eukaryotes such as mammals, 80S ribosomes are able to hydrolyze ATP without the addition of soluble protein factors. In addition, mammalian ribosomal ATPase activity cannot be removed with 0.5 M KCl and is only poorly removed with 2 M LiCl (14, 22). However, there has been no evidence of a third elongation factor in mammalian ribosomes, and the identity of the mammalian ribosomal ATPase activity remains unknown.
In order to further characterize the functional significance of EF3
amino acid differences between basidiomycetes and ascomycetes, CnEF3 was tested for its ability to replace the function of
YEF3 in vivo. It was found that CnEF3 only poorly
complemented either of two temperature-sensitive mutants of S. cerevisiae (ts22 and ts27). In addition, the sizes of colonies of
a KC44
yef3::LEU2 null mutant
rescued by CnEF3 were significantly smaller than those rescued by YEF3. These results are in contrast to those of
Cholthurst et al., who showed good complementation and normal colony
size after complementation of these same strains using EF3
from the ascomycete C. albicans (6). The poor
complementation by CnEF3 in vivo may again be a reflection
of structural or functional differences between the elongation factors
of ascomycetes and basidiomycetes.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by NIH grant AI38258-04 and a grant from the American Lung Association.
We appreciate helpful comments from K. J. Kwon-Chung.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: College of Medicine, Rm. 888, m/c 735, 808 S. Wood St., Chicago, IL 60612. Phone: (312) 996-6070. Fax: (312) 996-5704. E-mail: prw{at}uic.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Andriole, V. T., and H. M. Kravetz. 1962. The use of amphotericin B in man. JAMA 180:269-272. |
| 2. | Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, D.C. |
| 3. |
Casadevall, A.,
E. D. Spitzer,
D. Webb, and M. G. Rinaldi.
1993.
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
Antimicrob. Agents Chemother.
37:1383-1386 |
| 4. | Chakraburtty, K., and F. J. Triana-Alonso. 1998. Yeast elongation factor 3: structure and function. Biol. Chem. 379:831-840[Medline]. |
| 5. | Colthurst, D. R., M. Santos, C. M. Grant, and M. F. Tuite. 1991. Candida albicans and three other Candida species contain an elongation factor structurally and functionally analogous to elongation factor 3. FEMS Microbiol. Lett. 64:45-49[CrossRef][Medline]. |
| 6. | Colthurst, D. R., B. S. Schauder, M. V. Hayes, and M. F. Tuite. 1992. Elongation factor 3 (EF3) from Candida albicans shows both structural and functional similarity to EF3 from Saccharomyces cerevisiae. Mol. Microbiol. 6:1025-1033[CrossRef][Medline]. |
| 7. |
Dasmahapatra, B., and K. Chakraburtty.
1981.
Protein synthesis in yeast. I. Purification and properties of elongation factor 3 from Saccharomyces cerevisiae.
J. Biol. Chem.
256:9999-10004 |
| 8. | Di Domenico, B. J., J. Lupisella, M. Sandbaken, and K. Chakraburtty. 1992. Isolation and sequence analysis of the gene encoding translation elongation factor 3 from Candida albicans. Yeast. 8:337-352[CrossRef][Medline]. |
| 9. |
Goldman, D. L.,
B. C. Fries,
S. P. Franzot,
L. Montella, and A. Casadevall.
1998.
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents.
Proc. Natl. Acad. Sci. USA
95:14967-14972 |
| 10. |
Gontarek, R. R.,
H. Li,
K. Nurse, and C. D. Prescott.
1998.
The N terminus of eukaryotic translation elongation factor 3 interacts with 18 S rRNA and 80 S ribosomes.
J. Biol. Chem.
273:10249-10252 |
| 11. | Hawksworth, D. L., and G. C. Ainsworth. 1995. Ainsworth and Bisby's dictionary of the fungi. CAB International, Walingford, Oxon, United Kingdom. |
| 12. |
Kambampati, R., and K. Chakraburtty.
1997.
Functional subdomains of yeast elongation factor 3: localization of ribosome-binding domain.
J. Biol. Chem.
272:6377-6381 |
| 13. | Kovalchuke, O., J. Ziehler, and K. Chakraburrty. 1995. Comparative analysis of ATPase of yeast elongation factor 3 and ATPase associated with Tetrahymena ribosomes. Biochimie 77:713-718[Medline]. |
| 14. | Kovalchuke, O., and K. Chakraburrty. 1994. Comparative analysis of ribosome-associated adenosinetriphosphatase (ATPase) from pig liver and the ATPase of elongation factor 3 from Saccharomyces cerevisiae. Eur. J. Biochem. 226:133-140[Medline]. |
| 15. | Lamb, D. C., A. Corran, B. C. Baldwin, J. Kwon-Chung, and S. L. Kelly. 1995. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett. 368:326-330[CrossRef][Medline]. |
| 16. | Otaka, E., and K. Kobata. 1978. Yeast ribosomal proteins. I. Characterization of cytoplasmic ribosomal proteins by two-dimensional gel electrophoresis. Mol. Gen. Genet. 162:259-268[CrossRef][Medline]. |
| 17. | Paugam, A., J. Dupouy-Camet, P. Blanche, J. P. Gangneux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976[Medline]. |
| 18. | Pinner, R. W., R. A. Hajjeh, and W. G. Powderly. 1995. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S103-S107. |
| 19. |
Qin, S. L.,
K. Moldave, and C. S. McLaughlin.
1987.
Isolation of the yeast gene encoding elongation factor 3 for protein synthesis.
J. Biol. Chem.
262:7802-7807 |
| 20. |
Qin, S. L.,
A. G. Xie,
M. C. Bonato, and C. S. McLaughlin.
1990.
Sequence analysis of the translational elongation factor 3 from Saccharomyces cerevisiae.
J. Biol. Chem.
265:1903-1912 |
| 21. |
Restrepo, B. I., and A. G. Barbour.
1989.
Cloning of 18S and 25S rDNAs from the pathogenic fungus Cryptococcus neoformans.
J. Bacteriol.
171:5596-5600 |
| 22. | Rodnina, M. V., A. I. Serebryanik, G. V. Ovcharenko, and A. V. El'Skaya. 1994. ATPase strongly bound to higher eukaryotic ribosomes. Eur. J. Biochem. 225:305-310[Medline]. |
| 23. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 24. |
Sandbaken, M. G., et al.
1990.
Protein synthesis in yeast: structural and functional analysis of the gene encoding elongation factor 3.
J. Biol. Chem.
265:15838-15844 |
| 25. | Sarthy, A. V., T. McGonigal, J. O. Capobianco, T. H. Holzman, K. A. Walter, D. A. Egan, and R. C. Goldman. 1997. High-level overexpression of yeast elongation factor 3 and detailed kinetic analysis using a coupled spectrophotometric assay. Anal. Biochem. 254:288-290[CrossRef][Medline]. |
| 26. | Sherman, F., and J. Hicks. 1991. Micromanipulation and dissection of asci. Methods Enzymol. 194:21-37[Medline]. |
| 27. |
Thompson, J. R.,
C. M. Douglas,
W. Li,
C. K. Jue,
B. Pramanik,
X. Yuan,
T. H. Rude,
D. L. Tofaletti,
J. R. Perfect, and M. Kurtz.
1999.
A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function.
J. Bacteriol.
181:444-453 |
| 28. | Thornewell, S. J., R. B. Peery, and P. L. Skatrud. 1997. Cloning and molecular characterization of CnTEF1 which encodes translation elongation factor 1 alpha in Cryptococcus neoformans. Fungal Genet. Biol. 22:84-91[CrossRef][Medline]. |
| 29. |
Triana-Alonso, F. J.
1995.
The elongation factor 3 unique in higher fungi and essential for protein biosynthesis is an E site factor.
J. Biol. Chem.
270:20473-20478 |
| 30. |
Varma, A., and K. J. Kwon-Chung.
1991.
Rapid method to extract DNA from Cryptococcus neoformans.
J. Clin. Microbiol.
29:810-812 |
| 31. | Walzer, P. D. 2000. Pneumocystis carinii, p. 2781-2795. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, Pa. |
| 32. |
Williamson, P. R.
1994.
Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase.
J. Bacteriol.
176:656-664 |
| 33. | Yamada, T., T. Fukuda, K. Tamura, S. Furukawa, and P. Songsri. 1993. Expression of the gene encoding a translational elongation factor 3 homolog of Chlorella virus CVK2. Virology 197:742-750[CrossRef][Medline]. |
| 34. |
Ypma-Wong, M. F.,
W. A. Fonzi, and P. S. Sypherd.
1992.
Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii.
Infect. Immun.
60:4140-4145 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |